ImmunityBio reports $75 million in year-to-date sales and narrows net loss for Q3 2025
I'm PortAI, I can summarize articles.
ImmunityBio Inc. reported a significant increase in product revenue, reaching $31.8 million in Q3 2025, up 434% from $6.0 million in Q3 2024. Year-to-date sales totaled $74.7 million, a 467% increase in unit volume compared to the same period last year. The net loss for Q3 2025 was $67.3 million, improved from $85.7 million in Q3 2024. For the first nine months of 2025, the net loss was $289.5 million, down from $354.4 million in 2024. As of September 30, 2025, the company had $257.8 million in cash and equivalents.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments